 Beam Therapeutics Inc NASDAQ: BEAM has announced preclinical data for its cytosine base editors CBEs. The data demonstrate the potential of CBEs to reduce viral markers, including hepatitis B surface antigen HBsAg expression, and prevent viral rebound of hepatitis B virus HBV in in vitro models. 